Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion

The Food and Drug Administration issued guidance for evaluating the cardiovascular risk of new diabetes mellitus drugs in 2008. Accumulating evidence from several completed trials conducted within this framework raises questions as to whether requiring safety outcome studies for all new diabetes mel...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur Heart J Cardiovasc Pharmacother
Main Authors: Zannad, Faiez, Stough, Wendy Gattis, Lipicky, Raymond J., Tamargo, Juan, Bakris, George L., Borer, Jeffrey S., Alonso García, Maria de los Angeles, Hadjadj, Samy, Koenig, Wolfgang, Kupfer, Stuart, McCullough, Peter A., Mosenzon, Ofri, Pocock, Stuart, Scheen, André J., Sourij, Harald, Van der Schueren, Bart, Stahre, Christina, White, William B., Calvo, Gonzalo
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2016
Assuntos:
Reviews
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4907355/
https://ncbi.nlm.nih.gov/pubmed/27418973
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ehjcvp/pvw007
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados